FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2889773014> ?p ?o ?g. }

• W2889773014 endingPage "229" @default.
• W2889773014 startingPage "222" @default.
• W2889773014 abstract "The tumor necrosis factor (TNF) antagonist infliximab was previously found to reduce depressive symptoms in patients with treatment-resistant major depression (TRD) who exhibited high baseline inflammation, as reflected by plasma C-reactive protein (CRP) >5 mg/L. Further predictors of antidepressant response to infliximab included differential expression of peripheral blood gene transcripts that were related not only to inflammation but also to glucose and lipid metabolism. To determine whether plasma biomarkers of glucose and lipid metabolism were similarly associated with antidepressant response to infliximab and with relevant gene transcripts, we measured concentrations of glucose, insulin, and protein hormones that regulate glucose homeostasis and metabolism (leptin, resistin, and adiponectin), as well as cholesterols, triglycerides, and non-esterified fatty acids (NEFA), in medically-stable TRD outpatients at baseline and 2 weeks after the first infusion of infliximab (n = 26) or placebo (n = 26). Treatment response was defined as 50% reduction in depressive symptoms at any point during the 12-week trial. We found that baseline cholesterol (total, low-density lipoprotein [LDL], and non-high-density lipoprotein [non-HDL]), triglycerides and NEFA were elevated in patients who exhibited an antidepressant response to infliximab (all p < 0.05) but not placebo (all p > 0.299). HDL and non-HDL cholesterol concentrations also correlated with two lipid-related gene transcripts that were predictive of antidepressant response (r = 0.33 to 0.39, p < 0.05). Although not associated with response to infliximab, resistin correlated with numerous glucose-related transcripts (r = −0.32 to 0.37, p < 0.05) and was higher at 2 weeks post-infusion in patients treated with infliximab compared to placebo (p = 0.028). Concentrations of cholesterol (total, LDL, HDL, non-HDL) were also lower at 2 weeks in patients treated with infliximab compared to placebo, but only in those patients with CRP >5 mg/L at baseline (all p < 0.05). These results are consistent with previous work showing that high inflammation in patients with depression is associated with metabolic alterations, which together predict response to both traditional and experimental antidepressant therapies. Additionally, our findings suggest a causal relationship between increased inflammation and high cholesterol in depression, as a single infusion of infliximab reduced cholesterol in TRD patients with high CRP compared to placebo." @default.
• W2889773014 created "2018-09-27" @default.
• W2889773014 creator A5002965978 @default.
• W2889773014 creator A5047370210 @default.
• W2889773014 creator A5059583278 @default.
• W2889773014 creator A5076322374 @default.
• W2889773014 creator A5082654985 @default.
• W2889773014 creator A5085103683 @default.
• W2889773014 creator A5085475946 @default.
• W2889773014 date "2018-12-01" @default.
• W2889773014 modified "2023-10-17" @default.
• W2889773014 title "Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression" @default.
• W2889773014 cites W1557181977 @default.
• W2889773014 cites W1597227996 @default.
• W2889773014 cites W1966084594 @default.
• W2889773014 cites W1968702861 @default.
• W2889773014 cites W1972153696 @default.
• W2889773014 cites W1974373780 @default.
• W2889773014 cites W1990532967 @default.
• W2889773014 cites W2002796662 @default.
• W2889773014 cites W2010502047 @default.
• W2889773014 cites W2012067669 @default.
• W2889773014 cites W2021581084 @default.
• W2889773014 cites W2022930571 @default.
• W2889773014 cites W2024726128 @default.
• W2889773014 cites W2046120374 @default.
• W2889773014 cites W2051180837 @default.
• W2889773014 cites W2054093295 @default.
• W2889773014 cites W2064412851 @default.
• W2889773014 cites W2072781226 @default.
• W2889773014 cites W2079246886 @default.
• W2889773014 cites W2082182063 @default.
• W2889773014 cites W2089999836 @default.
• W2889773014 cites W2091259554 @default.
• W2889773014 cites W2106787748 @default.
• W2889773014 cites W2113929941 @default.
• W2889773014 cites W2118233432 @default.
• W2889773014 cites W2136812855 @default.
• W2889773014 cites W2153797344 @default.
• W2889773014 cites W2158677809 @default.
• W2889773014 cites W2163092745 @default.
• W2889773014 cites W2166449272 @default.
• W2889773014 cites W2168393830 @default.
• W2889773014 cites W2170973130 @default.
• W2889773014 cites W2196461303 @default.
• W2889773014 cites W2205259970 @default.
• W2889773014 cites W2235730659 @default.
• W2889773014 cites W2293576268 @default.
• W2889773014 cites W2343601477 @default.
• W2889773014 cites W2469101786 @default.
• W2889773014 cites W2504468643 @default.
• W2889773014 cites W2507921187 @default.
• W2889773014 cites W2519381186 @default.
• W2889773014 cites W2523234092 @default.
• W2889773014 cites W2770913451 @default.
• W2889773014 cites W2789034326 @default.
• W2889773014 cites W2794246920 @default.
• W2889773014 cites W2804087978 @default.
• W2889773014 cites W2808599394 @default.
• W2889773014 cites W4249727000 @default.
• W2889773014 doi "https://doi.org/10.1016/j.psyneuen.2018.09.004" @default.
• W2889773014 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6214671" @default.
• W2889773014 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30249443" @default.
• W2889773014 hasPublicationYear "2018" @default.
• W2889773014 type Work @default.
• W2889773014 sameAs 2889773014 @default.
• W2889773014 citedByCount "41" @default.
• W2889773014 countsByYear W28897730142019 @default.
• W2889773014 countsByYear W28897730142020 @default.
• W2889773014 countsByYear W28897730142021 @default.
• W2889773014 countsByYear W28897730142022 @default.
• W2889773014 countsByYear W28897730142023 @default.
• W2889773014 crossrefType "journal-article" @default.
• W2889773014 hasAuthorship W2889773014A5002965978 @default.
• W2889773014 hasAuthorship W2889773014A5047370210 @default.
• W2889773014 hasAuthorship W2889773014A5059583278 @default.
• W2889773014 hasAuthorship W2889773014A5076322374 @default.
• W2889773014 hasAuthorship W2889773014A5082654985 @default.
• W2889773014 hasAuthorship W2889773014A5085103683 @default.
• W2889773014 hasAuthorship W2889773014A5085475946 @default.
• W2889773014 hasBestOaLocation W28897730142 @default.
• W2889773014 hasConcept C126322002 @default.
• W2889773014 hasConcept C134018914 @default.
• W2889773014 hasConcept C17991360 @default.
• W2889773014 hasConcept C2776782570 @default.
• W2889773014 hasConcept C2777138892 @default.
• W2889773014 hasConcept C2777391703 @default.
• W2889773014 hasConcept C2778163477 @default.
• W2889773014 hasConcept C2778270857 @default.
• W2889773014 hasConcept C2779177272 @default.
• W2889773014 hasConcept C2779306644 @default.
• W2889773014 hasConcept C2779760629 @default.
• W2889773014 hasConcept C2779772378 @default.
• W2889773014 hasConcept C2780072125 @default.
• W2889773014 hasConcept C2780613262 @default.
• W2889773014 hasConcept C2781161787 @default.
• W2889773014 hasConcept C4733338 @default.
• W2889773014 hasConcept C511355011 @default.

• next